API
< Back to all clusters
[HEALTH] · United States, Australia · 3 sources

started · updated

Lemborexant insomnia drug reviews show high discontinuation rates

A study published in the journal Sleep Medicine, involving researchers from Rutgers Brain Health Institute, Virginia Commonwealth University, and the University of Sydney, has analyzed online patient experiences with the insomnia medication lemborexant.

By examining 260 online reviews posted between 2020 and 2023, researchers found that approximately one in four reviewers had either stopped or planned to stop taking the drug. While clinical trials indicated that lemborexant, sold as Dayvigo, helps patients fall asleep faster and stay asleep longer by blocking orexin signals, real-world feedback shows a sharp divide in patient satisfaction.

Roughly one third of reviewers reported meaningful sleep improvement. However, those who discontinued the medication cited side effects as a primary reason. One reviewer described a sensation of being unable to move or scream, while others reported highly polarized experiences, with ratings frequently splitting between the lowest and highest possible scores.

Entities

Dayvigo · Rutgers Brain Health Institute · University of Sydney · Virginia Commonwealth University